New hope for rare brain disease: drug may slow decline
NCT ID NCT06529146
First seen Jan 09, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This study looks at whether the drug troriluzole can slow down spinocerebellar ataxia (SCA), a rare brain disease that affects movement and balance. About 900 people with SCA who took troriluzole for up to 3 years are compared to a group of untreated patients from a natural history study. The goal is to see if the drug helps keep symptoms like walking and coordination from getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINOCEREBELLAR ATAXIAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biohaven
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.